Marianne Dibrino

Array ( [id] => 17236687 [patent_doc_number] => 11180559 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies [patent_app_type] => utility [patent_app_number] => 15/868704 [patent_app_country] => US [patent_app_date] => 2018-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 41 [patent_no_of_words] => 34059 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15868704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16776595 [patent_doc_number] => 20210113672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => METHOD OF VALIDATING THE TRIGGERING OF AN IMMUNE RESPONSE TO A NEOEPITOPE OF A TUMOR WITH T-CELLS [patent_app_type] => utility [patent_app_number] => 16/465675 [patent_app_country] => US [patent_app_date] => 2017-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12706945 [patent_doc_number] => 20180127481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => RECOMBINANT pMHC CLASS II MOLECULES [patent_app_type] => utility [patent_app_number] => 15/807415 [patent_app_country] => US [patent_app_date] => 2017-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42996 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15807415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778021 [patent_doc_number] => 20210115099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => PEPTIDES [patent_app_type] => utility [patent_app_number] => 16/347384 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12724381 [patent_doc_number] => 20180133294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => COMPOSITIONS AND METHODS RELATED TO GRAFT VERSUS HOST DISEASE AND TREATMENTS THEREOF [patent_app_type] => utility [patent_app_number] => 15/793731 [patent_app_country] => US [patent_app_date] => 2017-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15793731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14653337 [patent_doc_number] => 20190233797 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => HLA CLASS I-DEFICIENT NK-92 CELLS WITH DECREASED IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 16/337996 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17118763 [patent_doc_number] => 11129872 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => Methods of making and using soluble MHC molecules [patent_app_type] => utility [patent_app_number] => 15/674815 [patent_app_country] => US [patent_app_date] => 2017-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 41 [patent_no_of_words] => 18220 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15674815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17904359 [patent_doc_number] => 11458193 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-04 [patent_title] => Combination of vaccination and inhibition of MHC class I restricted antigen presentation [patent_app_type] => utility [patent_app_number] => 15/656730 [patent_app_country] => US [patent_app_date] => 2017-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14489 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15656730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12126257 [patent_doc_number] => 20180009843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'MODULATION OF ANTIGEN IMMUNOGENICITY BY DELETING EPITOPES RECOGNIZED BY NKT CELLS' [patent_app_type] => utility [patent_app_number] => 15/650784 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13311 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15026051 [patent_doc_number] => 20190324030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => MHC-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES [patent_app_type] => utility [patent_app_number] => 16/312956 [patent_app_country] => US [patent_app_date] => 2017-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -131 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16312956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712743 [patent_doc_number] => 20190247435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => NEOANTIGENS AS TARGETS FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/312152 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16312152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16061029 [patent_doc_number] => 10689446 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => Recombinant CD74 polypeptides [patent_app_type] => utility [patent_app_number] => 15/629573 [patent_app_country] => US [patent_app_date] => 2017-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 6693 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15629573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18575506 [patent_doc_number] => 11732020 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => T cell receptors and uses thereof [patent_app_type] => utility [patent_app_number] => 16/309902 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 19468 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16309902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717145 [patent_doc_number] => 20170369527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => METHOD FOR AFFINITY PURIFICATION [patent_app_type] => utility [patent_app_number] => 15/616781 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8240 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15616781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19327003 [patent_doc_number] => 12044680 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-23 [patent_title] => Peptide exchange system and method [patent_app_type] => utility [patent_app_number] => 16/301381 [patent_app_country] => US [patent_app_date] => 2017-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 32 [patent_no_of_words] => 9573 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16301381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14375231 [patent_doc_number] => 20190161528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => CLAUDIN-6 PEPTIDES [patent_app_type] => utility [patent_app_number] => 16/097587 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11834640 [patent_doc_number] => 20170216358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'METHODS AND COMPOSITIONS FOR MODIFICATION OF HLA' [patent_app_type] => utility [patent_app_number] => 15/490601 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 23583 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15490601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12233153 [patent_doc_number] => 20180066017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'CLASS I MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS' [patent_app_type] => utility [patent_app_number] => 15/483274 [patent_app_country] => US [patent_app_date] => 2017-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 7736 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15483274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16290330 [patent_doc_number] => 10767167 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes [patent_app_type] => utility [patent_app_number] => 15/481452 [patent_app_country] => US [patent_app_date] => 2017-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 27 [patent_no_of_words] => 15071 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15481452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11822138 [patent_doc_number] => 20170211076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'FUSION PROTEINS, USES THEREOF AND PROCESSES FOR PRODUCING SAME' [patent_app_type] => utility [patent_app_number] => 15/480462 [patent_app_country] => US [patent_app_date] => 2017-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 13815 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15480462 [rel_patent_id] =>[rel_patent_doc_number] =>)